Compare · GLP-1 agonist
Semaglutide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Semaglutide | VK2735 | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.
VK2735
VK2735 is an investigational obesity drug from Viking Therapeutics. It belongs to the incretin class — the same broad family as semaglutide and tirzepatide — and has generated a lot of attention because its early human data look strong and because Viking is developing both an injectable and an oral…